RASGRF1 (Phospho-S916)  polyclonal Antibody | BS64139

RASGRF1 (Phospho-S916)  polyclonal Antibody | BS64139 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Application: WB

Application Range: WB: 1:500~1:1000

Background: A critical step in signal transduction responses to stimulation of cell surface receptors by their ligands involves the accumulation of Ras proteins in their active GTP-bound state. To reach their active GTP-bound state, Ras proteins must first release bound GDP, a rate-limiting step mediated by a guanine nucleotide releasing factor (GRF) . The mammalian Ras p21 GRF protein has been designated Ras-GRF p140. Ras-GRF accelerates release of GDP from H- and N-Ras p21 protein in vitro, but not from the related Ral A or Cdc42Hs GTP-binding proteins. Of interest, a region mapping within the amino terminal domain of Ras-GRF is similar to both the human breakpoint cluster protein, Bcr, and the Dbl proto-oncogene product, a guanine nucleotide-releasing factor for CDC42Hs. Ras-GRF2 p135 has also been identified. Ras-GRF2 p135 is highly homologous to Ras-GRF1 p140 except in the region between the REM and CDC25 domains and appears to function similarly to Ras-GRF1 p140.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: RASGRF1 (Phospho-S916) polyclonal Antibody detects endogenous levels of RASGRF1 protein only when phosphorylated at Ser916.

Molecular Weight: ~ 145 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Ras-specific guanine nucleotide-releasing factor 1; Ras-GRF1; Guanine nucleotide-releasing protein; GNRP; Ras-specific nucleotide exchange factor CDC25; RASGRF1; CDC25; GNRP; GRF1

Immunogen: Synthetic phosphopeptide derived from human RASGRF1 around the phosphorylation site of Serine 916.

Conjugate: Unconjugated

Modification: Phosphorylation

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: Tumor Angiogenesis,Cell Cycle Control G1 S Checkpoint,Contribution of Soluble Factors to EMT,ESC Pluripotency and Differentiation Signaling Pathway,hippo Signaling,hippo Signaling,